INNOVADERM-RESEARCH
Innovaderm, a leading CRO in dermatology, has expanded its biometrics capacity following the acquisition of Excelsus Statistics, a Montreal-based company specialized in biostatistical and SAS programming services with a special expertise in adaptive trial design, as well as activities in many different therapeutic areas.
“We are pleased to grow our Biometrics team with the addition of new talent,” says Dr. Robert Bissonnette, Innovaderm’s founder and CEO. “Innovaderm has a reputation for excellence in clinical research in dermatology, as well as attracting committed professionals in the field. Our collective expertise will allow us to offer biometrics services across different therapeutic areas and fulfill the growing needs of our clients.”
Since 2014, Excelsus Statistics has served as a collaborator in many studies managed by Innovaderm. The integration of the two companies will allow Excelsus Statistics’ existing clients to now have access to full CRO services including data management in addition to statistical services.
“I am very excited because our experience in statistics and study management coupled with Innovaderm’s international reputation is a win-win situation,” says Diane Potvin, president of Excelsus Statistics. “This is a tremendous opportunity to consolidate resources and drive research forward.”
Innovaderm is a full-service CRO that is known for its excellent in-house data management and biostatistical services. It offers a wide range of biometrics services including protocol design, writing of statistical analysis plans, statistical programming, interpretation and reporting of data for clinical trial reports and publications, and statistical and strategic consulting for product development.
For more information on Innovaderm’s services, visit our website .
Innovaderm Research Inc.
Innovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OBJECTWAY18.4.2024 15:29:26 CEST | Press release
Kinsted Wealth Selects Objectway for Enhanced and Fully Integrated Client and Investment Management Platform to Drive Growth
NV-RIMINI-STREET18.4.2024 15:01:35 CEST | Press release
Rimini Street Honored with Two Prestigious Stevie® 2024 Awards in the Category of Customer Service
MN-KINDEVA-DRUG-DELIVERY18.4.2024 15:01:35 CEST | Press release
Denis Johnson Joins Kindeva Drug Delivery as Chief Operating Officer to Lead Global Operations
CA-DATAPLOR18.4.2024 15:01:35 CEST | Press release
dataplor Announces Series A Funding Led by Spark Capital to Expand Global Location Data Intelligence
MA-VERTEX-PHARMACEUTICAL18.4.2024 14:01:34 CEST | Press release
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom